NCT05923268View on ClinicalTrials.gov

Molecular Imaging of HER2 Expression in Breast Cancer Using [99mTc]Tc-G3-(G3S)3C Before Chemo/Targeted Therapy

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 4, 2023

Primary Completion Date

June 15, 2024

Study Completion Date

June 15, 2024

Conditions
Breast Cancer Female
Interventions
DRUG

[99mTc]Tc-G3-(G3S)3C

One single injection of \[99mTc\]Tc-G3-(G3S)3C, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours

Trial Locations (1)

Unknown

Olga, Tomsk

All Listed Sponsors
lead

Tomsk National Research Medical Center of the Russian Academy of Sciences

OTHER

NCT05923268 - Molecular Imaging of HER2 Expression in Breast Cancer Using [99mTc]Tc-G3-(G3S)3C Before Chemo/Targeted Therapy | Biotech Hunter | Biotech Hunter